The specialty drugs market will see more approvals in 2017 than 2016. Top areas to watch include cancer, multiple sclerosis, and HIV.
Pharmacy Best Practices
The FDA pushes back on new painkiller’s abuse-deterrent claims. Here’s why this is important to the opioid epidemic.
A new study uses population health analytics to identify potential opioid abuse, and the study findings are troubling.
Recently, FDA Commissioner Scott Gottlieb announced the FDA will move to close loopholes in the Orphan Drug Program. Here’s what you need to know.
Consider these five opportunities to help curb one of the biggest public health issues of the year.
An eye-opening Canadian study has surprising findings about the risk of death and antidepressants.
More support for clinical trials and a wider lens for rare diseases in children sets the category on fire.
A new study has shocking results about beta blocker use in heart-attack survivors.
PBMs partnering with pharmacies and drug makers may have a solution to nonadherence due to high pharma costs.
As more specialty drugs are approved, cost control strategies are key.